Health Innovation Manchester, a delegation of healthcare researchers, academia and industry will showcase Manchester’s MedTech capabilities at AdvaMed 2016, North America’s largest MedTech conference taking place in Minneapolis and will continue to Boston and Chicago as part of a health innovation roadshow.
This is the first time Health Innovation Manchester is travelling to the US to highlight the city’s strengths in MedTech and Manchester’s excellence in research and health informatics, which includes the world’s first large-scale, real time randomised clinical trial, the Salford Lung Study, making the region a top location for global MedTech and BioTech companies. The roadshow also provides the opportunity to connect with a number of industry, academic and clinical institutions along with investors and potential customers and will also be a catalyst to forge relationships with the United States and drive the next wave of innovation.
Sir Richard Leese, Leader of Manchester City Council, said: “Greater Manchester is recognised as one of the UK’s top three life science clusters with almost 11,500 people working in pharmaceutical, biotechnology and medical technology businesses.
“Our world-class strengths include a strong research-led university base, six major teaching hospitals, a successful record of clinical trials, a rich history of innovation and a wide industrial base. It also has the only accredited Academic Health Science Centre in the UK outside the South East, which is a powerful platform to widen Greater Manchester’s business base and growth.”
A competitive business destination for US companies to expand their MedTech operations across the Atlantic, Manchester is already home to American life sciences companies including Waters Corporation and Hologic. In addition to this, Medtronic has forged a partnership with one of the region’s hospital trusts that is worth over £50m.
Rowena Burns, chair of Health Innovation Manchester, said: “Our vision is to transform the health and well-being of the people of Greater Manchester by accelerating the discovery, development and delivery of new treatments and processes.
“To help us achieve this it’s important that Greater Manchester showcases its world-class assets in healthcare, clinical research, innovation and academia to a global audience, so our presence at AdvaMed is a great opportunity to not only understand the latest sector trends and thinking but to build new contacts and networks.
“We hope this will lead to fresh collaboration and bring inward investment to the city region with the ultimate goal of providing better healthcare outcomes for the people of Greater Manchester and beyond.”
The aim of the visit is to seek international innovation partners to address the specific unmet healthcare needs of the 2.7 million people in Greater Manchester, and beyond. This affords unique opportunities to test and adopt new innovation directly into the National Health Service through local commissioning.
Tim Newns, chief executive officer, MIDAS, Manchester’s inward investment agency, said: “As Manchester is the only city in the UK to take control of its £6bn health and social care budget, businesses will soon find it easier than ever before to engage with Manchester’s world-class health sector and will benefit from being able to move much more quickly from the lab to having an impact on people in the UK, and ultimately around the world.
“Over 200 biomedical companies are located in Greater Manchester, contributing £4bn to the local economy and it is the most invested in city in the UK outside London. The US is Manchester’s number one country for foreign direct investment and we are always seeking opportunities to forge R&D collaborations and welcome companies looking to get a foothold in the UK.
“Following the EU Referendum, this roadshow is the perfect platform for Health Innovation Manchester to connect with a number of industry, academic and clinical institutions along with investors and potential customers outside Europe. Manchester has a positive outlook post-Brexit and we look forward to engaging with potential international innovation partners.
“Greater Manchester is incredibly well connected, flying to over 200 international destinations. We already fly direct to 11 cities in the US including Chicago, Boston, Washington and New York, making it the perfect location for American companies to set up operations.”
- ENDS -
Notes to editors
Health Innovation Manchester has been established by Greater Manchester Health and Social Care to drive innovation into this system. Our role is to act as a system coordinator, partnering with academia, industry and healthcare providers, helping to connect emerging research with industry innovators, accelerating the development and adoption of innovations and aligning them with the region’s most pressing health and social care challenges.
Our partnership, with a single focus on Greater Manchester’s citizens, will work primarily through existing organisations, creating a ‘one team’ approach, collectively agreeing key priorities and ways of working. Operating in conjunction with the wider work of Greater Manchester devolution, we are working across the entire Greater Manchester Health and Social Care system, aligning priorities, skills and assets.
The United States delegation includes: Thomas Renn, Managing Director and Anne Doran, Head of Innovation & Partnerships, Manchester Science Partnerships; Professor Jackie Oldham, Director, Corridor Manchester; ; Mike Burrows, Managing Director, Greater Manchester Academic Health Science Network; Professor Carol Haigh, Professor in Nursing, Manchester Metropolitan University; Suzie Ali-Hassan, Business Development Manager, Northern Health Science Alliance; Zoher Kapacee, Business Research Manager, University of Manchester, Dr Leanne Burgin, Team Leader, Development & Partnering, University of Manchester Intellectual Property; Professor Martin Gibson, Chief Executive, NorthWest EHealth; and Tim Newns, Chief Executive Office, MIDAS, Manchester’s inward investment agency.